HC Wainwright Issues Positive Forecast for Ocugen Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Ocugen in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.05) per share for the quarter, up from their prior forecast of ($0.06). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at $0.18 EPS, FY2029 earnings at $0.84 EPS and FY2030 earnings at $1.79 EPS.

Ocugen (NASDAQ:OCGN) last released its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The business had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million.

Several other research firms have also weighed in on OCGN. Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Ocugen in a research note on Wednesday. Wall Street Zen upgraded Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Canaccord Genuity Group began coverage on Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target on the stock. Oppenheimer initiated coverage on Ocugen in a research note on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.75.

Ocugen Stock Performance

Shares of OCGN stock opened at $1.96 on Friday. The company has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $1.53. Ocugen has a one year low of $0.57 and a one year high of $2.73. The stock has a market cap of $642.68 million, a P/E ratio of -8.52 and a beta of 2.75. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06.

Institutional Trading of Ocugen

A number of hedge funds have recently modified their holdings of the stock. SmartHarvest Portfolios LLC acquired a new position in Ocugen in the 4th quarter valued at about $31,000. Schonfeld Strategic Advisors LLC bought a new position in Ocugen in the 4th quarter valued at about $38,000. Verdence Capital Advisors LLC acquired a new stake in Ocugen during the third quarter worth approximately $47,000. Cora Capital Advisors LLC lifted its position in Ocugen by 27.5% during the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after acquiring an additional 6,500 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Ocugen by 28,222.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after acquiring an additional 30,198 shares during the period. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised near‑term 2026 quarterly EPS forecasts to about ($0.05) and boosted multi‑year projections (FY2028–FY2030 materially higher), reiterated a “Buy” rating and lifted its price target to $10 — a very bullish long‑term signal for upside if pipeline milestones are met. HC Wainwright Forecast
• Positive Sentiment: Chardan Capital reaffirmed a “Buy” rating and a $7 price target, providing additional analyst support and another buy‑side endorsement for the story. Chardan Capital Note
• Neutral Sentiment: Consensus full‑year 2026 EPS remains negative (~($0.20)); most analyst moves still assume loss‑making 2026 results while projecting recovery in later years — keeps Ocugen a high‑volatility, binary biotech bet.
• Negative Sentiment: Phase II data for OCU410 (gene therapy for an eye disease) showed lower lesion reduction than prior results, prompting investor concern about the program’s durability and near‑term clinical risk; that report has driven selling pressure on the stock. Phase II OCU410 Coverage
• Negative Sentiment: Noble Financial trimmed Q3 and Q4 2026 EPS forecasts and lowered FY2026 expectations (slightly deeper loss), signaling at least one sell‑side view that near‑term operating/clinical momentum is weaker than previously thought.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.